ZAP70 (SBZAP)
- Known as:
- ZAP70 (SBZAP)
- Catalog number:
- NBP1-28572
- Product Quantity:
- 0.1 mg
- Category:
- -
- Supplier:
- ACR
- Gene target:
- ZAP70 (SBZAP)
Related genes to: ZAP70 (SBZAP)
- Gene:
- ZAP70 NIH gene
- Name:
- zeta chain of T cell receptor associated protein kinase 70
- Previous symbol:
- SRK
- Synonyms:
- ZAP-70, STD
- Chromosome:
- 2q11.2
- Locus Type:
- gene with protein product
- Date approved:
- 1995-05-16
- Date modifiied:
- 2019-04-23
Related products to: ZAP70 (SBZAP)
70 kDa zeta-associated protein,Homo sapiens,Human,SRK,Syk-related tyrosine kinase,Tyrosine-protein kinase ZAP-70,ZAP7070 kDa zeta-associated protein,Mouse,Mus musculus,Srk,Syk-related tyrosine kinase,Tyrosine-protein kinase ZAP-70,Zap70,Zap-70Active ZAP70Active ZAP70anti-ZAP70anti-ZAP70anti-ZAP70anti-ZAP70 (2F6)anti-ZAP70 (11H40)anti-ZAP70 (11H40)anti-ZAP70 (11H40) type: Primary antibodies host: MouseAnti-ZAP70 (11H40), Mouse Monoclonal to ZAP70, Isotype , Host Mouseanti-ZAP70 (2F6)anti-ZAP70 (3D2A4)anti-ZAP70 (49B4) Related articles to: ZAP70 (SBZAP)
- Chronic lymphocytic leukemia (CLL) is a heterogeneous haematological malignancy characterized by variable rates of progression, treatment requirements and survival. Zeta-chain-associated protein kinase 70 (ZAP-70) is a biologically informative marker historically associated with aggressive CLL biology, although it is no longer considered a standard-of-care prognostic marker where contemporary molecular prognostic testing is available. This review examines the role of ZAP-70 in the laboratory assessment, prognosis and clinical management of CLL, focusing on flow-cytometric measurement and integrated risk stratification. We synthesize the available literature and data showing that increased B-cell receptor signaling and ZAP-70 expression are correlated with shorter time to first treatment, disease progression and inferior survival, as well as with unmutated immunoglobulin heavy-chain variable-region genes. We further evaluate its prognostic value in relation to CD38, CD49d, β2-microglobulin, TP53 disruption, fluorescence in situ hybridization abnormalities and Rai and Binet staging. Laboratory factors that affect clinical implementation are discussed, such as antibody clone selection, fixation and permeabilization, gating strategies, internal controls, positivity thresholds and quantitative reporting. We also examine complementary assessment by quantitative PCR, immunohistochemistry and DNA methylation analysis, as well as the evolving role of ZAP-70 in the targeted-therapy era. The implementation of ZAP-70 assessment in laboratory practice requires harmonized analytical workflows, standardized interpretation and prospective validation. This review provides a laboratory-medicine perspective on the historical and biological relevance of ZAP-70, its analytical limitations, and its restricted contemporary role, including possible adjunctive use where molecular prognostic testing is delayed or unavailable. - Source: PubMed
Publication date: 2026/09/28
Thapa RiyaFuloria Neeraj KumarIqbal Muhammad ZahidOrayj Khalid MBhat Asif AhmadNarain KamalBhatia SumitaSingh SaurabhBiswas AnupamFuloria Shivkanya - Erythroleukemia is a malignant hematological disorder often accompanied by severe immunosuppression, with T cell dysfunction playing a central role. Gastrodin, which is derived from Gastrodia elata, has been proven to possess various pharmacological activities such as neuroprotection and immunomodulation. However, whether it can effectively improve the immune function in erythroleukemia has not been reported. Our results demonstrated that gastrodin treatment significantly alleviated splenomegaly and inhibited the malignant progression in erythroleukemia mice. Moreover, it markedly enhanced the proliferative capacity of splenic T cells and promoted the secretion of immune - related cytokines. Mechanistically, gastrodin upregulated the expression of key molecules in the T cell receptor signaling pathway, including LCK, ZAP-70, ITK, PKC, IKK, and NFκB, at both the mRNA and protein phosphorylation levels. Notably, through integrated bioinformatics analysis, molecular docking, and cellular thermal shift assays, we found that gastrodin exhibits moderate interaction with the transcription factor Fli-1 in erythroleukemia. Collectively, this study provides the first evidence that gastrodin enhances splenic immune function in erythroleukemia by modulating the T cell receptor (TCR) signaling pathway. Cellular thermal shift assay identified Fli-1 as a protein capable of physically interacting with gastrodin, although its functional contribution remains to be further explored. These findings highlight gastrodin as a promising immunotherapeutic candidate for erythroleukemia. - Source: PubMed
Publication date: 2026/09/19
Cheng ShaXu YingjiangWang JianpingYu JiaHu LiangliangLiu JimingLuo Heng - Chimeric antigen receptor (CAR)-T cell therapy has emerged as a transformative cancer immunotherapy, employing genetic engineering to express CARs in patient T cells. CARs are composed of a single-chain variable fragment (scFv), hinge, transmembrane, and intracellular signaling domains. While scFv directly recognizes tumor-associated antigens, the hinge domain connects the scFv to intracellular signaling domains, determining the formation of immunological synapse (IS). Because IS is critical for CAR activation, optimizing hinge length is crucial for successful CAR-T cell therapy. Here, we developed a novel dimerization-dependent fluorescent protein (ddFP)-based IS biosensor, named CAR-D, to investigate hinge length effects on CAR activation. CAR-D consists of a CAR fused to ddFP-A and a ZAP70-tSH2 domain fused to ddFP-B. Upon CAR engagement with the target antigen, CAR phosphorylation recruits ZAP70-tSH2, triggering ddFP-A/ddFP-B dimerization and generating a fluorescent signal that reports CAR activation at the IS in real time. Using the CAR-D system, we assessed CARs with different hinge lengths targeting distinct epitopes of two tumor-associated antigens, mesothelin (MSLN) and HER2, and determined threshold hinge lengths for CAR activation. Our results revealed a strong correlation between threshold hinge length and the distance from scFv to the target epitope, implying that hinge length optimization is crucial for effective CAR-T cell therapy. Furthermore, the CAR-D system provides a valuable tool for predicting CAR efficacy and guiding future CAR engineering strategies. - Source: PubMed
Publication date: 2026/09/18
Jo HyunminLee Seung EunLee Hae NimHong JisuLee Chang-HanKim Hang-RaeSeong Jihye
- Source: PubMed
- Inositol 1,4,5-trisphosphate receptor-interacting protein-like 1(ITPRIPL1) has recently been implicated in tumor-immune regulation, yet its tumor-type specificity and clinical relevance in gastrointestinal malignancies remain unclear. Here, we performed an integrative analysis of ITPRIPL1 across stomach adenocarcinoma (STAD), colon adenocarcinoma (COAD), rectal adenocarcinoma (READ), and esophageal carcinoma (ESCA) using bulk transcriptomics, immune pathway analyses, survival modeling, single-cell RNA sequencing, immunofluorescence validation, and therapeutic correlation analyses. Although ITPRIPL1 was upregulated across gastrointestinal cancers, its prognostic significance was highly tumor-specific, with elevated expression consistently predicting unfavorable survival only in STAD. In gastric cancer, ITPRIPL1 expression was closely associated with immune-related pathways and genomic instability features, and its prognostic association varied across immune contexts, particularly according to CD8⁺/CD4⁺ T-cell abundance, with an exploratory association also observed for zeta-chain-associated protein kinase 70 (ZAP70) expression. Single-cell and immunofluorescence analyses demonstrated preferential enrichment of ITPRIPL1 in T cells and tumor-adjacent immune structures. Notably, Exploratory analyses further showed that higher ITPRIPL1 expression was associated with favorable survival outcomes in selected external pretreatment immunotherapy cohorts and with lower IC50 values for several agents in cancer cell-line pharmacogenomic datasets. Collectively, these findings identify ITPRIPL1 as an immune-associated biomarker with primary clinical relevance in gastric cancer. - Source: PubMed
Publication date: 2026/07/30
Lyu YahuiLyu HanzhangGuo GuodongZhao HongmeiLin WeitengWang YouqingChen HongHuang QiXue FangqinWang NingLin JinlanTian Yue